The two topics are only linked by the fact that they both have been on my mind this week. Novartis recently received approval to market a renin inhibitor…a major accomplishment if you are familiar with this target. I am in the process of writing up a small piece on this…expect it soon.
I am playing with the idea of using “idiosynsyncratic”, as in idiosyncratic drug reactions, as the word of the week. I realize it is a topic that most of us have become very familiar with over the last few years. It is really just a chance to add my two cents to the discussion concerning this issue.